# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** canonical_hrd_parp_synthetic_lethality_model
- **Hypothesis Label:** Canonical HRD-PARP Synthetic Lethality Model
- **Status in KB:** CANONICAL

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: canonical_hrd_parp_synthetic_lethality_model
hypothesis_label: Canonical HRD-PARP Synthetic Lethality Model
status: CANONICAL
description: HGSOC HRR or FA/BRCA pathway deficiency creates a tumor-specific defect in high-fidelity
  double-strand-break repair, converting PARP-inhibitor-induced single-strand break accumulation and platinum-induced
  interstrand crosslinks into selectively lethal lesions. This is the canonical synthetic-lethal exploitation
  that underpins maintenance olaparib benefit and is the disease-level instantiation of the dna_repair_synthetic_lethality
  module's canonical hypothesis.
evidence:
- reference: PMID:33475295
  supports: SUPPORT
  evidence_source: OTHER
  snippet: PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1
    and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer.
  explanation: Review evidence directly supports PARP-inhibitor synthetic lethality in BRCA-associated
    tumors as the canonical mechanism.
- reference: PMID:36082969
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: At 7 years, 67.0% of olaparib patients versus 46.5% of placebo patients were alive, and 45.3%
    versus 20.6%, respectively, were alive and had not received a first subsequent treatment
  explanation: SOLO1 long-term survival benefit is the clinical embodiment of HRD-PARP synthetic lethality
    in HGSOC.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.

**Provider:** asta
**Generated:** 2026-05-26T23:12:28.774655

1. Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al. (2018). Gathering Evidence of Mechanisms. https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
2. C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al. (2009). PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
3. T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al. (2018). An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
4. Christopher G. Smith (2017). A Resident’s Perspective of Ovarian Cancer. Diagnostics. https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
5. S. Labidi-Galy, E. Papp, Dorothy Hallberg, N. Niknafs, V. Adleff et al. (2017). High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. https://www.semanticscholar.org/paper/b491df3d0b6c859c6170c9c1a949e044cc7fce0e
6. J. Skogen, S. Øverland (2012). The fetal origins of adult disease: a narrative review of the epidemiological literature. JRSM Short Reports. https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
7. G. Saed, R. T. Morris, N. Fletcher (2018). New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress. Ovarian Cancer - From Pathogenesis to Treatment. https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
8. F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al. (2018). A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. NPJ Systems Biology and Applications. https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
9. Y. Man, A. Stojadinovic, J. Mason, I. Avital, A. Bilchik et al. (2013). Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories. Journal of Cancer. https://www.semanticscholar.org/paper/8cc82beaad33d7a1809ec739e2457ede0db158b4
10. M. Köbel, S. Kalloger, Niki Boyd, S. McKinney, Erika Mehl et al. (2008). Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine. https://www.semanticscholar.org/paper/eb0d584d28493e3219c8618f32f90ec6d43d04db
11. D. Jelovac, D. K. Armstrong (2011). Recent Progress in the Diagnosis and Treatment of Ovarian Cancer. CA: a cancer journal for clinicians. https://www.semanticscholar.org/paper/96bac6c0748ab090fe304e3578072cf81bf6998d
12. Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin et al. (2025). DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research. ArXiv. https://www.semanticscholar.org/paper/f06a59cb27b36766098ecb235c9ada048e145ed0
13. Lang Qin, Z. Gan, Xu Cao, Pengcheng Jiang, Yankai Jiang et al. (2025). RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases. ArXiv. https://www.semanticscholar.org/paper/ad0dc7cd9de3e46fb22cc025706d54dfe58331a0
14. Christophe Gerard Lambert, L. Black (2012). Learning from our GWAS mistakes: from experimental design to scientific method. Biostatistics (Oxford, England). https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
15. Rubén Romero-Córdoba, J. Olivas, F. P. Romero, Francisco Alonso-Gómez, J. Serrano-Guerrero (2017). An Application of Fuzzy Prototypes to the Diagnosis and Treatment of Fuzzy Diseases. International Journal of Intelligent Systems. https://www.semanticscholar.org/paper/36623f163659f9e4d1cf968252e10e36faa19676
16. Keren Levanon, V. Ng, H. Piao, Yi Zhang, Martin C. Chang et al. (2009). Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. https://www.semanticscholar.org/paper/a30e02ca02a8859a9ed7f4650aeae4d6b1693fcf
17. M. T. Rahman, K. Nakayama, Munmun Rahman, H. Katagiri, A. Katagiri et al. (2013). KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas. International Journal of Molecular Sciences. https://www.semanticscholar.org/paper/b70c68e39f0258ef0a2cc08056fd4d14e13be01e
18. Zilin Xianyu, Cristina Correia, C. Ung, Shizhen Zhu, D. Billadeau et al. (2024). The Rise of Hypothesis-Driven Artificial Intelligence in Oncology. Cancers. https://www.semanticscholar.org/paper/f05721d59597ea5471ac85617fda99b4e73fb936
